Picture of Senseonics Holdings logo

SENS Senseonics Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+8.08%
3m-27.28%
6m+135.5%
1yr+66.68%
Volume Change (%)
10d/3m-73.42%
Price vs... (%)
52w High-46.06%
50d MA+3.28%
200d MA+40.9%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-121.52%
Return on Equity-817.17%
Operating Margin-333.05%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Senseonics Holdings EPS forecast chart

Profile Summary

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

Directors

Last Annual
December 31st, 2024
Last Interim
December 31st, 2024
Incorporated
December 4th, 2015
Public Since
March 4th, 2015
No. of Shareholders
156
No. of Employees
117
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
654,216,092

SENS Share Price Performance

Upcoming Events for SENS

Q1 2025 Senseonics Holdings Inc Earnings Release

Senseonics Holdings Inc Annual Shareholders Meeting

Q2 2025 Senseonics Holdings Inc Earnings Release

Similar to SENS

FAQ